Disitertide (diammonium)

O=C([C@@H](N)[C@@H](C)O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C([O-])=O)CC(N)=O)=O)CCC(N)=O)=O)CCSC)=O)CCSC)=O)C)=O)CC1=CNC2=CC=CC=C12)=O)[C@H](CC)C)=O)[C@H](CC)C)=O)CO)=O)C)=O)CC([O-])=O)=O)CC(C)C)=O)CO.[NH4+].[NH4+]

[1]Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.|[2]Jun Yang, et al. Upregulation of microRNA-590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor-β1/phosphoinositide 3-kinase/Akt signaling. Int J Mol Med. 2019 May;43 (5) :2212-2220.|[3]Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38 (23) :4637-4654.|[4]Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10 (12) :e0144489.|[5]Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381 (1) :67-75.

Dig Dis Sci. 2025 May;70 (5) :1799-1812.|Acta Histochem. 2023 Feb;125 (2) :152010.|Cancer Manag Res. 2018 Oct 10:10:4459-4470.|Cell Death Differ. 2021 Jan;28 (1) :219-232.|Cells. 2019 Jun 25;8 (6) :635.|Dig Dis Sci. 2021 Jun;66 (6) :1916-1927.|Eur Rev Med Pharmacol Sci. 2019 Aug;23 (3 Suppl) :9-16. |Front Immunol. 2017 Feb 3:8:91.|Int J Mol Med. 2019 May;43 (5) :2212-2220. |J BUON. 2021; 26 (2) : 435-443.|J Exp Clin Cancer Res. 2021 Feb 9;40 (1) :62.|Oncogene. 2019 Jun;38 (23) :4637-4654.|Funct Integr Genomics. 2024 Jul 12;24 (4) :123.|Int Immunopharmacol. 2024 Aug 21:141:112778.|Int J Surg. 2025 Jul 9.